Strategies to Reduce Cannabinoid Psychoactivity Need Their Own Outcome Evidence
A 2009 clinical-perspective review discussed several strategies intended to separate cannabinoid analgesia from unwanted psychoactivity. A plausible targeting strategy is not the same as demonstrated preservation of cognition or function.
The strategies changed different aspects of treatment
The review considered formulation, CBD addition, peripheral or CB2 targeting, local delivery and manipulation of endogenous signaling. These approaches are not interchangeable interventions. Each requires evidence for its actual preparation and intended outcome.
Less psychoactivity and more analgesia are separate claims
A favorable pain-response result does not establish that subjective effects, sedation or complex performance are unaffected. Conversely, reducing a subjective effect does not prove that the desired therapeutic effect remains. The separation itself must be tested.
The synthesis was a historical development perspective
The source summarized promising approaches and their limitations as understood in 2009. It should not be used as a current safety endorsement for all cannabinoid combinations or a clinical instruction to add CBD or opioids.
Interpreting the evidence
A strategy should be assessed by the benefit retained and the adverse outcome actually measured. The review maps candidate approaches, not a universal method for producing non-impairing cannabis analgesia or safely altering another medicine's dose.
Related reading: interpreting cannabis tolerance claims.
Research reference
Karst M; Wippermann S (2009). Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert opinion on investigational drugs. doi:10.1517/13543780802691951.
This analysis draws on the supplied review abstract.
